<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet type="text/xsl" href="static/style.xsl"?><OAI-PMH xmlns="http://www.openarchives.org/OAI/2.0/" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="http://www.openarchives.org/OAI/2.0/ http://www.openarchives.org/OAI/2.0/OAI-PMH.xsd"><responseDate>2026-11-21T06:05:41Z</responseDate><request verb="GetRecord" identifier="oai:macsphere.mcmaster.ca:11375/16287" metadataPrefix="dim">https://prod-ms-be.lib.mcmaster.ca/server/oai/request</request><GetRecord><record><header><identifier>oai:macsphere.mcmaster.ca:11375/16287</identifier><datestamp>2026-09-24T18:48:20Z</datestamp><setSpec>com_11375_271</setSpec><setSpec>col_11375_272</setSpec></header><metadata><dim:dim xmlns:dim="http://www.dspace.org/xmlns/dspace/dim" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xmlns:doc="http://www.lyncode.com/xoai" xsi:schemaLocation="http://www.dspace.org/xmlns/dspace/dim http://www.dspace.org/schema/dim.xsd">
   <dim:field mdschema="dc" element="contributor" qualifier="advisor">Tang, Damu</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="author">De Melo, Jason Anthony</dim:field>
   <dim:field mdschema="dc" element="contributor" qualifier="department" lang="en_US">Medical Sciences</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="accessioned">2014-11-05T17:31:21Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="available">2014-11-05T17:31:21Z</dim:field>
   <dim:field mdschema="dc" element="date" qualifier="issued">2014-11</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">http://hdl.handle.net/11375/16287</dim:field>
   <dim:field mdschema="dc" element="identifier" qualifier="uri">https://doi.org/10.71548/14657</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="abstract" lang="en_US">As the primary antagonist to the tumorigenic PI3K/AKT pathway, PTEN is classified as a tumor suppressor. The inactivation of PTEN through genetic or post-translational modifications is a critical step in the tumorigenesis of many breast cancers (BCs). SIPL1 is a novel protein which was identified as a PTEN negative regulator. To further explore SIPL1-mediated PTEN inactivation, we analyzed 17 datasets covering 3484 BC cases and 228 normal individuals. SIPL1 gene amplification and increased mRNA expression correlates with the progression and poor prognosis of ER and/or PR positive tumors. Furthermore, examination of a BC tissue microarray containing 224 tumor cases revealed elevated SIPL1 protein expression in ER+ and PR+ tumors and was associated with greater AKT activation. Additionally, ectopic expression of SIPL1 in CHO-K1 cells resulted in increased AKT activation and cell proliferation, and cytoskeleton reorganization alongside with PTEN downregulation.&#xd;
   SIPL1 contributes to the linear polyubiquitination of NEMO, suggesting a role for SIPL1 in PTEN ubiquitination. Indeed, it was SIPL1, not the SIPL1-∆UBL (a PTEN-binding defective mutant) which robustly induced PTEN polyubiquitination in a lysine (K) 63-dependent but K48-independent manner. While K48-linked polyubiquitin chains direct protein degradation, K63-linked chains regulate a variety of protein functions. SIPL1 binds polyubiquitinated PTEN with significantly higher affinity than non-ubiquitinated PTEN. A SIPL1 mutant, SIPL1-TFLV, is unable to cause PTEN ubiquitination but is capable of PTEN association. Collectively, our results reveal that SIPL1 interacts with PTEN with a low affinity, which results in PTEN polyubiquitination, and that the modification may stabilize the association between SIPL1 and PTEN. We propose a model where SIPL1 mediates the K63-linked ubiquitination of PTEN inactivating it. The downregulation of PTEN, when paired with the tumor-promoting effects of ER and/or PR, stimulates breast tumorigenesis. SIPL1 is an important BC marker and future research should focus on its potential as a therapeutic target.</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degreetype" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="dc" element="description" qualifier="degree" lang="en_US">Doctor of Philosophy (PhD)</dim:field>
   <dim:field mdschema="dc" element="language" qualifier="iso" lang="en_US">en</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Breast Cancer</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Tumourigenesis</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">PTEN</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">PI3k/AKT Pathway</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Ubiquitination</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">SIPL1</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Protein-Protein Interaction</dim:field>
   <dim:field mdschema="dc" element="subject" lang="en_US">Cancer</dim:field>
   <dim:field mdschema="dc" element="title" lang="en_US">CHARACTERIZATION OF SIPL1-MEDIATED PTEN INACTIVATION DURING TUMORIGENESIS</dim:field>
   <dim:field mdschema="dc" element="title" qualifier="alternative" lang="en_US">INACTIVATION OF PTEN BY SIPL1</dim:field>
   <dim:field mdschema="dc" element="type" lang="en_US">Thesis</dim:field>
   <dim:field mdschema="others" element="access-status">open.access</dim:field>
</dim:dim></metadata></record></GetRecord></OAI-PMH>